Mar 24, 2020   SOURCE: PR NewsWire

Global Catheter-Related Bloodstream Infection (CRBSI) Industry Insights, Epidemiology, and Outlook to 2028

DUBLIN, March 24, 2020 /PRNewswire/ -- The "Catheter-Related Bloodstream Infection (CRBSI) -Market Insights, Epidemiology, and Market Forecast-2028" drug pipelines has been added to ResearchAndMarkets.com's offering.

http://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

This report delivers an in-depth understanding of the catheter-related bloodstream infection, historical and forecasted epidemiology as well as the catheter-related bloodstream infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia.

Study Period: 2017-2028

Diagnosis

The diagnosis of catheter-related bloodstream infection remains a major challenge. Fever and chills that are often associated with catheter-related bloodstream infections are not specific. Furthermore, local catheter inflammation and phlebitis could exist in the absence of catheter-related bloodstream infection or even a local infection, as has been reported with peripherally inserted central catheters.

The 'gold standard' for the diagnosis of catheter-related bloodstream infection is the combination of positive blood culture with the same organism isolated from the catheter. However, a major diagnostic problem is that traditional methods of catheter culture necessitate the removal of the central venous catheters (CVC), whereby the line tip is either rolled on an agar plate or placed in a nutrient broth.

Treatment

It covers the details of conventional and current medical therapies available in the catheter-related bloodstream infection market for the treatment of the condition. It also provides the treatment guidelines and algorithms of the United States and Spain.

The catheter-related bloodstream infection market report gives a thorough understanding of catheter-related bloodstream infection by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis.

Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Population of Catheter-Related Bloodstream Infection Total Diagnosed Incident Population of Catheter-Related Bloodstream Infection, and Diagnosed Incidence of Catheter-Related Bloodstream Infection by Causative Pathogens scenario of catheter-related bloodstream infection in the global market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia from 2017 to 2028.

Key Findings

This section provides glimpses of the catheter-related bloodstream infection epidemiology in the global market.

As per the research analysis, the total incident population of catheter-related bloodstream infection in the global market was found to be 4,114,882 in 2017. The estimates show a higher incidence of catheter-related bloodstream infection in India with 1,722,280 cases in 2017.

Country-Wise Epidemiology

The epidemiology segment also provides the catheter-related bloodstream infection epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan, APAC (China, India, Taiwan, South Korea, and Australia), LATAM (Brazil, Mexico, Argentina, and Colombia), Middle East (Saudi Arabia and the United Arab Emirates), and Russia.

Drug Chapters

The drug chapter segment of the catheter-related bloodstream infection report encloses the detailed analysis of catheter-related bloodstream infection marketed drugs and late stage (phase III) pipeline drugs. It also helps to understand the catheter-related bloodstream infection clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

Neutrolin: CorMedix

Neutrolin (CRMD003), is a non-antibiotic, anti-infective developed by CorMedix as a preventative solution to decrease the threat of infection and blood clots (thrombosis), thereby keeping CVCs operating safely and efficiently. It is a catheter lock solution for the prevention of catheter-related bloodstream infection and maintenance of catheter patency in hemodialysis patients.

Taurosept: Geistlich Pharma

TauroSept is an antimicrobial solution (lock solution) developed by Geistlich Pharma for the prevention of catheter-related infection and is intended for installation in intravenous catheters between treatments to lock the catheter. It mainly contains antibacterial chemotherapeutic agent taurolidine.

Off-label Drugs

Daptomycin

Daptomycin is a cyclic lipopeptide parenteral antibiotic derived from Streptomyces roseosporus. It exhibits rapid concentration-dependent bactericidal activity against Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus (MRSA).

Vancomycin

Vancomycin is a tricyclic glycopeptide antibiotic originally derived from the organism Streptococcus orientalis. Vancomycin is used for the treatment and prevention of various bacterial infection caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

Emerging Drugs

Mino-Lok: Citius Pharmaceuticals

Mino-Lok is an antibiotic lock solution used to treat patients with central line-associated bloodstream infection/catheter-related bloodstream infection. It is a combination of minocycline, edetate (disodium EDTA), and ethyl alcohol, all of which act synergistically to break down bacterial biofilms, eradicate the bacteria, provide anti-clotting properties to maintain patency in CVCs, and salvage the indwelling catheter.

Market Outlook

The catheter-related bloodstream infection market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted catheter-related bloodstream infection market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

This segment gives a thorough detail of catheter-related bloodstream infection market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Key Findings

This section includes a glimpse of the catheter-related bloodstream infection global market. The market size of CRBSI in the Global market was USD 1,237.38 million in 2017.

The United States Market Outlook

This section provides the total catheter-related bloodstream infection market size and market size by therapies in the United States.

Among the Global Market, the United States had the highest market size of CRBSI in 2017, which accounts for approximately 55% of the total market. The growth of market size for CRBSI is attributed to currently prescribed treatment regimens as well as emerging therapies. The market size for CRBSI was found to be USD 381.5 million in 2017.

EU-5 Market Outlook

The total catheter-related bloodstream infection market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total catheter-related bloodstream infection market size and market size by therapies in Japan are provided.

APAC Market Outlook

The total catheter-related bloodstream infection market size and market size by therapies in China, India, Taiwan, South Korea, and Australia are provided in this section.

India accounts for approximately 34.7% of the total APAC market of CRBSI. The research estimations suggest that the overall market size of CRBSI will increase at a moderate pace with USD 178.72 million in 2017 to USD 189.32 million in 2022. This is due to the dependency on the market size of CRBSI on supportive treatment regimens.

LATAM Market Outlook

The total catheter-related bloodstream infection market size and market size by therapies in Brazil, Mexico, Argentina, and Colombia are provided.

Argentina accounts for 13.7% of the total LATAM market of CRBSI. The research estimates suggest that the overall market size of CRBSI will grow with USD 8.59 million in 2017 to USD 9.23 million in 2022. This is attributed to the dependency on the market size of CRBSI on supportive therapies for CRBSI.

Middle East Market Outlook

The total catheter-related bloodstream infection market size and market size by therapies in Saudi Arabia and the United Arab Emirates are provided in this section.

Russia Market Outlook

The total catheter-related bloodstream infection market size and market size by therapies in Russia are provided in this section.

Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the catheter-related bloodstream infection market or expected to get launched in the market during the study period 2017-2028. The analysis covers catheter-related bloodstream infection market uptake by drugs; patient uptake by therapies; and sales of each drug.

Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing and patent details for catheter-related bloodstream infection emerging therapies.

Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, the publisher considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL - Views

To keep up with current market trends, the publisher takes KOLs and SME's opinion working in catheter-related bloodstream infection domains through primary research to fill the data gaps and validate the secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or catheter-related bloodstream infection market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

This report was created using various competitive intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

    --  The report covers the descriptive overview of catheter-related
        bloodstream infection, explaining its causes, signs and symptoms,
        pathogenesis and currently available therapies.
    --  Comprehensive insight has been provided into the catheter-related
        bloodstream infection epidemiology and treatment.
    --  Additionally, an all-inclusive account of both the current and emerging
        therapies for catheter-related bloodstream infection are provided, along
        with the assessment of new therapies, which will have an impact on the
        current treatment landscape.
    --  A detailed review of catheter-related bloodstream infection market;
        historical and forecasted is included in the report, covering the global
        drug outreach.
    --  The report provides an edge while developing business strategies, by
        understanding trends shaping and driving the global catheter-related
        bloodstream infection market

Report Highlights

    --  In the coming years, catheter-related bloodstream infection market is
        set to change due to the rising awareness of the disease, and
        incremental healthcare spending across the world; which would expand the
        size of the market to enable the drug manufacturers to penetrate more
        into the market.
    --  The companies and academics are working to assess challenges and seek
        opportunities that could influence catheter-related bloodstream
        infection R&D. The therapies under development are focused on novel
        approaches to treat/improve the disease condition.
    --  Major players are involved in developing therapies for catheter-related
        bloodstream infection. Launch of emerging therapies will significantly
        impact the catheter-related bloodstream infection market
    --  The in-depth analysis of the pipeline assets across different stages of
        development (phase III and phase II), different emerging trends and
        comparative analysis of pipeline products with detailed clinical
        profiles, key cross-competition, launch date along with product
        development activities will support the clients in the decision-making
        process regarding their therapeutic portfolio by identifying the overall
        scenario of the research and development activities.

Report Insights

    --  Patient Population
    --  Therapeutic Approaches
    --  Catheter-Related Bloodstream Infection Pipeline Analysis
    --  Catheter-Related Bloodstream Infection Market Size and Trends
    --  Market Opportunities
    --  Impact of upcoming Therapies

Key Strengths

    --  Nine Years Forecast
    --  Global Coverage
    --  Catheter-Related Bloodstream Infection Epidemiology Segmentation
    --  Key Cross Competition
    --  Highly Analyzed Market
    --  Drugs Uptake

Report Assessment

    --  Current Treatment Practices
    --  Unmet Needs
    --  Pipeline Product Profiles
    --  Market Attractiveness
    --  Market Drivers and Barriers

Companies Mentioned 

    --  CorMedix
    --  Geistlich Pharma
    --  TauroPharm GmbH
    --  Fresenius Medical Care

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/nn562r

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-catheter-related-bloodstream-infection-crbsi-industry-insights-epidemiology-and-outlook-to-2028-301028845.html

SOURCE Research and Markets